Detalhe da pesquisa
1.
PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.
Blood
; 134(14): 1176-1189, 2019 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31383640
2.
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Blood
; 128(7): 959-70, 2016 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27307294
3.
Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.
Blood
; 128(25): 2949-2959, 2016 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27733356
4.
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.
J Immunol
; 197(3): 807-13, 2016 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27316683
5.
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
Mol Ther
; 25(8): 1946-1958, 2017 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28506593
6.
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Haematologica
; 101(5): 616-25, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26858358
7.
Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.
Haematologica
; 105(2): e80-e83, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31123033
8.
Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma.
Blood
; 120(3): e9-e16, 2012 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22653974
9.
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Haematologica
; 104(3): e100-e103, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190344
10.
Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2.
Sci Adv
; 10(20): eadk9076, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748792
11.
Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival.
Blood
; 117(23): 6162-71, 2011 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-21471524
12.
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138.
Clin Cancer Res
; 29(20): 4219-4229, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37527004
13.
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.
Nat Cancer
; 4(5): 754-773, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37237081
14.
Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.
Blood
; 115(3): 601-4, 2010 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965677
15.
N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Haematologica
; 96(11): 1653-61, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21828122
16.
Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.
Haematologica
; 101(8): e339-42, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27151995
17.
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant.
Hemasphere
; 5(5): e561, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33898931
18.
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis.
Clin Cancer Res
; 27(13): 3793-3803, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33883175
19.
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Sci Transl Med
; 13(623): eabh1962, 2021 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34878825
20.
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
Cell Rep
; 34(1): 108532, 2021 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33406420